EUCTR2018-003168-29-BE
Active, Not Recruiting
Phase 1
[18F]PSMA-11 PET/CT for prostate cancer – phase 3 clinical trial
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- prostate cancer
- Sponsor
- Ghent University Hospital
- Enrollment
- 96
- Status
- Active, Not Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients diagnosed with prostate cancer, either in the setting of diagnosis of biochemical recurrence after previous treatment, or at primary diagnosis and staging
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 19
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 77
Exclusion Criteria
- •\- Age \< 18 years
- •\- Physically or mentally unfit to perform the sequential procedures
- •\- Refusal of patient to be informed about accidental findings on scans
- •\- History of anaphylactic shock after administration of Visipaque CT contrast
- •\- Serum creatinine concentration \> 2\.0 mg/dl and/or estimated glomerular filtration rate \< 60 ml/min
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
PSMA-PET/CT for prostate cancerEUCTR2017-003461-96-BEGhent University Hospital72
Completed
Phase 3
[18F]PSMA-11 PET/CT Phase 3 Clinical StudyProstate CancerNCT03911310University Hospital, Ghent96
Active, Not Recruiting
Phase 1
18F-PSMA PET in primary prostate cancer.75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients with PIRADS 3 (equivocal disease) and 25 patients with PIRADS 4-5 (highly suspicious for malignancy) will be included in this explorative study.MedDRA version: 20.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001387-28-NLRadboud University Medical Center75
Completed
Phase 2
18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathologyNL-OMON49534Radboud Universitair Medisch Centrum75
Recruiting
Phase 3
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028Prostate CancerNCT05520255University of Alberta2,800